Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice

for the HABS-HD Study Team

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Despite the clinical implementation, there remain significant gaps in our knowledge regarding the impact of race/ethnicity or common medical comorbidity on plasma Alzheimer's disease (AD) biomarkers. Methods: Plasma biomarkers of amyloid beta (Aβ)40,42, total tau, and neurofilament light chain (NfL) were measured across cognitively normal Mexican Americans (n = 445) and non-Hispanic Whites (n = 520). Results: Dyslipidemia was associated with elevated Aβ40 (P =.01) and Aβ42 (P =.001) while hypertension was associated with elevated Aβ40 (P =.003), Aβ42 (P <.001), and total tau (P =.002) levels. Diabetes was associated with higher Aβ40 (P <.001), Aβ42 (P <.001), total tau (P <.001), and NfL (P <.001) levels. Chronic kidney disease (CKD) was associated with elevations in Aβ40 (P <.001), Aβ42 (P <.001), total tau (P <.001), and NfL (P <.001) levels. Mexican Americans had significantly lower Aβ40 (P <.001) and higher total tau (P =.005) levels. Discussion: Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity. These findings are important for those using these biomarkers in clinical practice and clinical trials.

Original languageEnglish
JournalAlzheimer's and Dementia
DOIs
StateAccepted/In press - 2022

Keywords

  • Alzheimer's disease
  • Mexican Americans
  • health disparities
  • plasma biomarkers

Fingerprint

Dive into the research topics of 'Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice'. Together they form a unique fingerprint.

Cite this